ClinicalTrials.gg
CompletedNCT01813422GLAGOVUpdated Feb 20, 2019Results posted

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

A Phase 3 interventional study of Evolocumab and Placebo in Hypercholesterolemia, sponsored by Amgen. Completed at 226 sites in 32 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-02-20.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
970
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
7th of 36
970 · median 308
Started
2013
with 10 others
Phase 3
22 of 36
none open now
Registered
14th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 7th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab (AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78 than placebo in adults with coronary artery disease taking lipid lowering therapy.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Cholesterol
  • High Cholesterol
  • Elevated Cholesterol
  • Raised Cholesterol
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical indication for coronary angiography
  • Subjects already taking statin therapy, niacin or ezetimibe at screening must have been on a stable dose for at least 4 weeks prior to screening LDL-C. Subjects not taking lipid-regulating therapy must enter the study via a lipid stabilization period. Subjects who are intolerant to statins must meet statin intolerance entry criteria
  • Fasting LDL-C ≥ 80 mg/dL (2.07 mmol/L) with or without additional risk factors, or, LDL-C ≥ 60 -\< 80 mg/dL (1.55-2.07 mmol/L) in the presence of one major or three minor risk factors

Subjects must meet the following criteria at the qualifying coronary catheterization procedure:

  • Evidence of coronary heart disease (at least one lesion in a native coronary artery that has > 20% reduction in lumen diameter) or prior percutaneous intervention (PCI)
  • Left main coronary artery \< 50% reduction in lumen diameter by visual estimation
  • Target coronary artery for IVUS must be accessible to the IVUS catheter, must not have a > 50% reduction in lumen diameter within the target segment (and at least 40 mm in length); cannot have undergone prior PCI or coronary artery bypass graft (CABG) and is not a candidate for intervention over the next 18 months. It may not be a bypass graft, bypassed vessel or culprit vessel for previous myocardial infarction (MI).

Exclusion criteria

Exclusion Criteria:

  • Coronary artery bypass graft surgery \< 6 weeks prior to the qualifying IVUS
  • (NYHA) III or IV heart failure, or last known less than 30%
  • Uncontrolled cardiac arrhythmia that is not controlled by medications in the 3 months prior to randomization
  • Known hemorrhagic stroke
  • Uncontrolled hypertension at randomization
  • Fasting Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at screening
  • Type 1 diabetes or poorly controlled type 2 diabetes ( [HbA1c] > 9%) at screening.
  • Moderate to severe renal dysfunction (estimated [eGFR] \< 30 ml/min/1.73m²) at screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
970 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.

    Drug: Placebo

  • Experimental
    Evolocumab

    Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha®

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Percent Atheroma Volume at Week 78

    Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma.

    Time frame: Baseline and week 78

Secondary outcomes

  1. Change From Baseline in Total Atheroma Volume at Week 78

    Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants.

    Time frame: Baseline and week 78

  2. Percentage of Participants With Regression in Percent Atheroma Volume

    Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma. Regression in PAV was defined as any reduction from baseline in PAV.

    Time frame: Baseline and week 78

  3. Percentage of Participants With Regression in Total Atheroma Volume

    Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants. Regression in TAV was defined as any reduction from baseline in TAV.

    Time frame: Baseline and week 78

07

Results

Posted Jan 4, 2018

Participant flow

This study was conducted at 163 centers in 30 countries in Europe, North America, Asia Pacific, and Latin America. The first participant was enrolled on 18 April 2013 and the last participant enrolled on 12 January 2015.

Participant flow — Overall Study
MilestonePlaceboEvolocumab
Started486484
Received treatment484484
Completed466468
Not completed2016
Withdrew: Withdrawal by subject148
Withdrew: Death23
Withdrew: Sponsor decision21
Withdrew: Lost to follow-up24

Outcome measures

PrimaryChange From Baseline in Percent Atheroma Volume at Week 78

Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma.

Time frame:
Baseline and week 78
Reported as:
Least squares mean · percent atheroma volume
Change From Baseline in Percent Atheroma Volume at Week 78
percent atheroma volumePlaceboEvolocumab
Change From Baseline in Percent Atheroma Volume at Week 780.053 ± 0.189-0.955 ± 0.190
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = < 0.0001 · Ls mean treatment difference: -1.007 · 95% CI -1.375 to -0.640Treatment difference uses placebo as the reference.
SecondaryChange From Baseline in Total Atheroma Volume at Week 78

Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants.

Time frame:
Baseline and week 78
Reported as:
Least squares mean · mm³
Change From Baseline in Total Atheroma Volume at Week 78
mm³PlaceboEvolocumab
Change From Baseline in Total Atheroma Volume at Week 78-0.910 ± 1.214-5.799 ± 1.216
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = < 0.0001 · Ls mean treatment difference: -4.889 · 95% CI -7.247 to -2.531Treatment difference uses placebo as the reference.
SecondaryPercentage of Participants With Regression in Percent Atheroma Volume

Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. The extent of atherosclerosis was expressed as percent atheroma volume (PAV) in a ≥ 40 mm segment of one targeted (imaged) coronary artery, calculated as the percentage of the total vessel volume occupied by atheroma. Regression in PAV was defined as any reduction from baseline in PAV.

Time frame:
Baseline and week 78
Reported as:
Number · percentage of participants
Percentage of Participants With Regression in Percent Atheroma Volume
percentage of participantsPlaceboEvolocumab
Percentage of Participants With Regression in Percent Atheroma Volume47.3 (42.6 to 52.0)64.3 (59.6 to 68.7)
Statistical analysis
  • Placebo vs Evolocumab · Cochran-Mantel-Haenszel · p = < 0.0001 · Treatment difference: 17.0 · 95% CI 10.3 to 23.5Treatment difference uses placebo as the reference.
SecondaryPercentage of Participants With Regression in Total Atheroma Volume

Intravascular ultrasound (IVUS) was used to visualize the extent of atherosclerotic plaques in the coronary artery lumen. Total atheroma volume (TAV) in a ≥ 40 mm segment of the targeted coronary artery was calculated as the average plaque area over the number of images that were evaluated by IVUS multiplied by the median vessel length to compensate for differences in segment length between participants. Regression in TAV was defined as any reduction from baseline in TAV.

Time frame:
Baseline and week 78
Reported as:
Number · percentage of participants
Percentage of Participants With Regression in Total Atheroma Volume
percentage of participantsPlaceboEvolocumab
Percentage of Participants With Regression in Total Atheroma Volume48.9 (44.2 to 53.7)61.5 (56.7 to 66.0)
Statistical analysis
  • Placebo vs Evolocumab · Cochran-Mantel-Haenszel · p = 0.0002 · Treatment difference: 12.5 · 95% CI 5.8 to 19.1Treatment difference uses placebo as the reference.

Adverse events

Collected over From first dose of study drug until week 80. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—142/484 (29.3%)120/484 (24.8%)
Evolocumab—135/484 (27.9%)114/484 (23.6%)
Most frequent serious events
Showing 10 of 213
Most frequent serious events
EventPlaceboEvolocumab
Angina pectorisCardiac disorders11/48417/484
Coronary artery diseaseCardiac disorders13/4847/484
Non-cardiac chest painGeneral disorders6/48411/484
Angina unstableCardiac disorders7/4848/484
Acute myocardial infarctionCardiac disorders5/4846/484
Atrial fibrillationCardiac disorders4/4846/484
Arteriosclerosis coronary arteryCardiac disorders5/4840/484
Coronary artery stenosisCardiac disorders5/4843/484
PneumoniaInfections and infestations5/4840/484
Myocardial infarctionCardiac disorders4/4840/484
Most frequent other events
Most frequent other events
EventPlaceboEvolocumab
MyalgiaMusculoskeletal and connective tissue disorders27/48434/484
HypertensionVascular disorders34/48429/484
Chest painGeneral disorders26/48433/484
Angina pectorisCardiac disorders32/48421/484
HeadacheNervous system disorders29/48419/484

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboEvolocumabTotal
Mean59.8 ± 8.859.8 ± 9.659.8 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEvolocumabTotal
Female135135270
Male351349700
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEvolocumabTotal
Hispanic or Latino243458
Not Hispanic or Latino462450912
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboEvolocumabTotal
American Indian or Alaska Native202
Asian171431
Native Hawaiian or Other Pacific Islander011
Black or African American549
White453456909
Multiple6713
Other325
Stratification Factor: Geographical Region
Stratification Factor: Geographical Region(participants)PlaceboEvolocumabTotal
North America8886174
Europe332332664
Latin America161531
Asia Pacific5051101
08

Study locations

226 sites
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Little Rock, Arkansas 72211, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    La Jolla, California 92093-0960, United States
  • Research Site
    Long Beach, California 90822, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    San Diego, California 92161, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Atlantis, Florida 33462, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Jacksonville, Florida 32209, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Melbourne, Florida 32901, United States
  • Research Site
    Safety Harbor, Florida 34695, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Hammond, Indiana 46320, United States
  • Research Site
    Valparaiso, Indiana 46383, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Louisville, Kentucky 40205, United States
  • Research Site
    Covington, Louisiana 70433, United States
  • Research Site
    Bethesda, Maryland 20814, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Bay City, Michigan 48708, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Marquette, Michigan 49855, United States
  • Research Site
    Midland, Michigan 48670, United States
  • Research Site
    Petoskey, Michigan 49770, United States
  • Research Site
    Saginaw, Michigan 48601, United States
  • Research Site
    Duluth, Minnesota 55805, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Saint Cloud, Minnesota 56303, United States
  • Research Site
    Saint Paul, Minnesota 55102, United States
  • Research Site
    Columbia, Missouri 65212, United States
  • Research Site
    Missoula, Montana 59802, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    Ridgewood, New Jersey 07450, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    Johnson City, New York 13790, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Fargo, North Dakota 58122, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Elyria, Ohio 44035, United States
  • Research Site
    Toledo, Ohio 43614, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Tulsa, Oklahoma 74104, United States
  • Research Site
    Hillsboro, Oregon 97123, United States
  • Research Site
    Springfield, Oregon 97477, United States
  • Research Site
    Doylestown, Pennsylvania 18901, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Oak Ridge, Tennessee 37830, United States
  • Research Site
    Amarillo, Texas 79106, United States
  • Research Site
    Dallas, Texas 75216, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Wichita Falls, Texas 76301, United States
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1428DCO, Argentina
  • Research Site
    La Plata, Buenos Aires 1900, Argentina
  • Research Site
    Cordoba, Córdoba X5000JHQ, Argentina
  • Research Site
    Cordoba, Córdoba X5016KEH, Argentina
  • Research Site
    Rosario, Santa Fe 2000, Argentina
  • Research Site
    Buenos Aires, C1280AEB, Argentina
  • Research Site
    Corrientes, W3400AMZ, Argentina
  • Research Site
    Córdoba, X5003DCE, Argentina
  • Research Site
    Concord, New South Wales 2139, Australia
  • Research Site
    Darlinghurst, New South Wales 2010, Australia
  • Research Site
    Liverpool, New South Wales 2170, Australia
  • Research Site
    New Lambton Heights, New South Wales 2305, Australia
  • Research Site
    Chermside, Queensland 4032, Australia
  • Research Site
    Herston, Queensland 4029, Australia
  • Research Site
    Adelaide, South Australia 5000, Australia
  • Research Site
    Bedford Park, South Australia 5042, Australia
  • Research Site
    Epping, Victoria 3076, Australia
  • Research Site
    Footscray, Victoria 3011, Australia
  • Research Site
    Heidelberg, Victoria 3084, Australia
  • Research Site
    Melbourne, Victoria 3004, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Antwerpen, 2020, Belgium
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Lodelinsart, 6042, Belgium
  • Research Site
    Cariacica, Espírito Santo 29156-580, Brazil
  • Research Site
    Goiania, Goiás 74223-130, Brazil
  • Research Site
    Curitiba, Paraná 80320-320, Brazil
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90020-090, Brazil
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90610-000, Brazil
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90620-001, Brazil
  • Research Site
    Sao Paulo, São Paulo 04012-909, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Edmonton, Alberta T5H 3V9, Canada
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada

Showing the first 100 of 226 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951. PubMed 27846344 ↗
  • Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078. PubMed 30336824 ↗
  • Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10(10):CD011748. doi: 10.1002/14651858.CD011748.pub3. PubMed 33078867 ↗
  • Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJ, Ballantyne CM, Koenig W, Anderson TJ, Yang J, Kassahun H, Wasserman SM, Scott R, Borgman M, Nicholls SJ. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun;176:83-92. doi: 10.1016/j.ahj.2016.01.019. Epub 2016 Feb 17. PubMed 27264224 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Jul 2016, 38 months.

Results were first posted in Jan 2018, 1 year 5 months after primary completion. A results delay was requested in Jun 2017.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 38 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2013
First posted
Mar 19, 2013
StartActual
Apr 18, 2013
Primary completionActual
Jul 12, 2016
CompletionActual
Jul 29, 2016
Results delay requested
Jun 19, 2017
Results first posted
Jan 4, 2018
Last update
Feb 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01813422
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 19, 2013
Start date
Apr 18, 2013
Primary completion
Jul 12, 2016
Completion
Jul 29, 2016
Results posted
Jan 4, 2018
Last update
Feb 20, 2019

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion